You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 29, 2024

Claims for Patent: 10,426,833


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 10,426,833
Title:Liquid pharmaceutical composition
Abstract: The present invention relates to novel liquid pharmaceutical compositions of adalimumab, which include adalimumab or a biosimilar thereof, a citrate buffering agent/system such as sodium citrate/citric acid, and a sugar stabilizer such as trehalose. Such a combination of components furnishes formulations having a stability (e.g. on storage and when exposed to stress) which is comparable to or an improvement upon those known in the art, and with fewer ingredients. Such advances will help adalimumab treatments to become more widely available at lower cost, and prolong the viability of pre-loaded delivery devices (e.g. prefilled syringes) to reduce unnecessary waste of the drug.
Inventor(s): Rinaldi; Gianluca (Monterotondo, IT), Fratarcangeli; Silvia (Ceprano, IT), Del Rio; Alessandra (Rome, IT)
Assignee: Fresenius Kabi Deutschland GmbH (Bad Homburg, DE)
Application Number:15/313,487
Patent Claims:1. An aqueous pharmaceutical composition comprising: (a) 45-55 mg/mL adalimumab; (b) 5-14 mM citrate buffer system; (c) 100-250 mM sugar stabilizer selected from the group consisting of trehalose and sorbitol; and (d) 0.05-1.5 mg/mL surfactant selected from the group consisting of polysorbate 80 and polysorbate 20; wherein the composition: has a pH between 5.0 and 6.0; is free of phosphate buffering agents; and is free of amino acids selected from the group consisting of arginine, lysine, and aspartic acid; and comprises at most one sugar stabilizer.

2. The aqueous pharmaceutical composition of claim 1, wherein the sugar stabiliser is present at a concentration of 100 to 210 mM.

3. The aqueous pharmaceutical composition of claim 1, wherein the citrate buffering agent or citrate buffer system is present at a concentration of 10 mM.

4. The aqueous pharmaceutical composition of claim 1, wherein the surfactant is present at a concentration of 0.5 to 1.1 mg/mL.

5. The aqueous pharmaceutical composition of claim 1, wherein the sugar stabiliser is sorbitol.

6. The aqueous pharmaceutical composition of claim 1, wherein the pH of the composition is from 5.0 to 5.4.

7. The aqueous pharmaceutical composition of claim 1, wherein the surfactant is polysorbate 20.

8. The aqueous pharmaceutical composition of claim 1, wherein the composition further comprises a histidine buffer.

9. The aqueous pharmaceutical composition of claim 1, wherein the sugar stabilizer is present at a concentration of 100 to 150 mM.

10. The aqueous pharmaceutical composition of claim 1, wherein the composition comprises a tonicifier which is the sugar stabilizer.

11. The aqueous pharmaceutical composition of claim 1, wherein the composition comprises only a single tonicifier, which is the sugar stabilizer.

12. The aqueous pharmaceutical composition of claim 1, wherein the composition is free of amino acids or is free of amino acids with the exception of histidine which may be present as a further buffer system.

13. The aqueous pharmaceutical composition of claim 1, wherein the composition consists of: (a) 45-55 mg/mL adalimumab; (b) a citrate buffer system alone or in combination with a further buffer system, wherein the citrate buffer system is present in the composition at a concentration of 5-14 mM; (c) 100-200 mM sorbitol; (d) 0.05-1.5 mg/mL polysorbate 20; and (e) water; wherein the composition has a pH between 5.0 and 6.0.

14. The aqueous pharmaceutical composition of claim 1, wherein the composition consists of: (a) 50 mg/mL adalimumab; (b) a citrate buffer system alone or in combination with a further buffer system, wherein the citrate buffer system is present in the composition at a concentration of 5-14 mM; (c) 100-150 mM sorbitol; (d) 0.5-1.1 mg/mL polysorbate 20; and (e) water; wherein the composition has a pH between 5.0 and 6.0.

15. The aqueous pharmaceutical composition of claim 1, wherein the composition consists of: (a) 50 mg/mL adalimumab; (b) a citrate buffer system alone or in combination with a further buffer system, wherein the citrate buffer system is present in the composition at a concentration of 10 mM; (c) 100-150 mM sorbitol; (d) 0.5-1.1 mg/mL polysorbate 20; and (e) water; wherein the composition has a pH between 5.0 and 5.4.

16. The aqueous pharmaceutical composition of claim 1, wherein the composition consists of: (f) 45-55 mg/mL adalimumab; (g) a citrate buffer system in combination with a histidine buffering agent or histidine buffer system, wherein the citrate buffer system is present in the composition at a concentration of 5-14 mM; (h) 100-200 mM sorbitol; (i) 0.05-1.5 mg/mL polysorbate 20; and (j) water; wherein the composition has a pH between 5.0 and 6.0.

17. The aqueous pharmaceutical composition of claim 1, wherein the composition consists of: (f) 50 mg/mL adalimumab; (g) a citrate buffer system in combination with a histidine buffering agent or histidine buffer system, wherein the citrate buffer system is present in the composition at a concentration of 5-14 mM; (h) 100-150 mM sorbitol; (i) 0.5-1.1 mg/mL polysorbate 20' and (j) water; wherein the composition has a pH between 5.0 and 6.0.

18. The aqueous pharmaceutical composition of claim 1, wherein the composition consists of: (f) 50 mg/mL adalimumab; (g) a citrate buffer system in combination with a histidine buffering agent or histidine buffer system, wherein the citrate buffer system is present in the composition at a concentration of 10 mM; (h) 100-150 mM sorbitol; (i) 0.5-1.1 mg/mL polysorbate 20; and (j) water; wherein the composition has a pH between 5.0 and 5.4.

19. The aqueous pharmaceutical composition of claim 1, wherein the composition comprises: the citrate buffer system in a molar ratio of citrate buffer system to adalimumab of from 14:1 to 40:1; the sugar stabilizer in a molar ratio of sugar stabilizer to adalimumab of from 290:1 to 860:1; and the surfactant in a molar ratio of surfactant to adalimumab of from 1:35 to 3:1.

Details for Patent 10,426,833

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Abbvie Inc. HUMIRA adalimumab Injection 125057 12/31/2002 ⤷  Try a Trial 2034-05-23
Abbvie Inc. HUMIRA adalimumab Injection 125057 02/21/2008 ⤷  Try a Trial 2034-05-23
Abbvie Inc. HUMIRA adalimumab Injection 125057 04/24/2013 ⤷  Try a Trial 2034-05-23
Abbvie Inc. HUMIRA adalimumab Injection 125057 09/23/2014 ⤷  Try a Trial 2034-05-23
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.